Abstract
Objectives: The evolution of EGFR tyrosine kinase inhibitors (TKIs) has changed the landscape of disease for a subset of patients with NSCLC. Most pat......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
